Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 376

1.

Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein.

Lu XH, Fleming SM, Meurers B, Ackerson LC, Mortazavi F, Lo V, Hernandez D, Sulzer D, Jackson GR, Maidment NT, Chesselet MF, Yang XW.

J Neurosci. 2009 Feb 18;29(7):1962-76. doi: 10.1523/JNEUROSCI.5351-08.2009.

2.

Parkin is protective for substantia nigra dopamine neurons in a tau gene transfer neurodegeneration model.

Klein RL, Dayton RD, Henderson KM, Petrucelli L.

Neurosci Lett. 2006 Jun 19;401(1-2):130-5. Epub 2006 Mar 22.

3.

LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function.

Sloan M, Alegre-Abarrategui J, Potgieter D, Kaufmann AK, Exley R, Deltheil T, Threlfell S, Connor-Robson N, Brimblecombe K, Wallings R, Cioroch M, Bannerman DM, Bolam JP, Magill PJ, Cragg SJ, Dodson PD, Wade-Martins R.

Hum Mol Genet. 2016 Mar 1;25(5):951-63. doi: 10.1093/hmg/ddv628. Epub 2016 Jan 6.

4.

A53T human α-synuclein overexpression in transgenic mice induces pervasive mitochondria macroautophagy defects preceding dopamine neuron degeneration.

Chen L, Xie Z, Turkson S, Zhuang X.

J Neurosci. 2015 Jan 21;35(3):890-905. doi: 10.1523/JNEUROSCI.0089-14.2015.

5.

Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease.

Lo Bianco C, Schneider BL, Bauer M, Sajadi A, Brice A, Iwatsubo T, Aebischer P.

Proc Natl Acad Sci U S A. 2004 Dec 14;101(50):17510-5. Epub 2004 Dec 2.

6.

Effects of UCH-L1 on alpha-synuclein over-expression mouse model of Parkinson's disease.

Yasuda T, Nihira T, Ren YR, Cao XQ, Wada K, Setsuie R, Kabuta T, Wada K, Hattori N, Mizuno Y, Mochizuki H.

J Neurochem. 2009 Feb;108(4):932-44. doi: 10.1111/j.1471-4159.2008.05827.x. Epub 2009 Jan 7.

7.

rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.

Oliveras-Salvá M, Van der Perren A, Casadei N, Stroobants S, Nuber S, D'Hooge R, Van den Haute C, Baekelandt V.

Mol Neurodegener. 2013 Nov 25;8:44. doi: 10.1186/1750-1326-8-44.

8.

Surprising behavioral and neurochemical enhancements in mice with combined mutations linked to Parkinson's disease.

Hennis MR, Marvin MA, Taylor CM 2nd, Goldberg MS.

Neurobiol Dis. 2014 Feb;62:113-23. doi: 10.1016/j.nbd.2013.09.009. Epub 2013 Sep 26.

9.

Mutant Twinkle increases dopaminergic neurodegeneration, mtDNA deletions and modulates Parkin expression.

Song L, Shan Y, Lloyd KC, Cortopassi GA.

Hum Mol Genet. 2012 Dec 1;21(23):5147-58. doi: 10.1093/hmg/dds365. Epub 2012 Sep 4.

10.

Aldehyde dehydrogenase 1 defines and protects a nigrostriatal dopaminergic neuron subpopulation.

Liu G, Yu J, Ding J, Xie C, Sun L, Rudenko I, Zheng W, Sastry N, Luo J, Rudow G, Troncoso JC, Cai H.

J Clin Invest. 2014 Jul;124(7):3032-46. doi: 10.1172/JCI72176. Epub 2014 May 27.

11.

Neurotoxicity and behavioral deficits associated with Septin 5 accumulation in dopaminergic neurons.

Son JH, Kawamata H, Yoo MS, Kim DJ, Lee YK, Kim S, Dawson TM, Zhang H, Sulzer D, Yang L, Beal MF, Degiorgio LA, Chun HS, Baker H, Peng C.

J Neurochem. 2005 Aug;94(4):1040-53.

12.

Parkin-mediated protection of dopaminergic neurons in a chronic MPTP-minipump mouse model of Parkinson disease.

Yasuda T, Hayakawa H, Nihira T, Ren YR, Nakata Y, Nagai M, Hattori N, Miyake K, Takada M, Shimada T, Mizuno Y, Mochizuki H.

J Neuropathol Exp Neurol. 2011 Aug;70(8):686-97. doi: 10.1097/NEN.0b013e3182269ecd.

PMID:
21760537
13.

Age-dependent effects of A53T alpha-synuclein on behavior and dopaminergic function.

Oaks AW, Frankfurt M, Finkelstein DI, Sidhu A.

PLoS One. 2013;8(4):e60378. doi: 10.1371/journal.pone.0060378. Epub 2013 Apr 1.

14.
15.

Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model.

Janezic S, Threlfell S, Dodson PD, Dowie MJ, Taylor TN, Potgieter D, Parkkinen L, Senior SL, Anwar S, Ryan B, Deltheil T, Kosillo P, Cioroch M, Wagner K, Ansorge O, Bannerman DM, Bolam JP, Magill PJ, Cragg SJ, Wade-Martins R.

Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):E4016-25. doi: 10.1073/pnas.1309143110. Epub 2013 Sep 30.

16.

Parkin deficiency increases vulnerability to inflammation-related nigral degeneration.

Frank-Cannon TC, Tran T, Ruhn KA, Martinez TN, Hong J, Marvin M, Hartley M, Treviño I, O'Brien DE, Casey B, Goldberg MS, Tansey MG.

J Neurosci. 2008 Oct 22;28(43):10825-34. doi: 10.1523/JNEUROSCI.3001-08.2008.

17.

Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression.

Maingay M, Romero-Ramos M, Carta M, Kirik D.

Neurobiol Dis. 2006 Sep;23(3):522-32. Epub 2006 Jun 30.

PMID:
16806952
18.

Nigral overexpression of alpha-synuclein in the absence of parkin enhances alpha-synuclein phosphorylation but does not modulate dopaminergic neurodegeneration.

Van Rompuy AS, Oliveras-Salvá M, Van der Perren A, Corti O, Van den Haute C, Baekelandt V.

Mol Neurodegener. 2015 Jun 23;10:23. doi: 10.1186/s13024-015-0017-8.

19.

Alpha-synuclein aggregation alters tyrosine hydroxylase phosphorylation and immunoreactivity: lessons from viral transduction of knockout mice.

Alerte TN, Akinfolarin AA, Friedrich EE, Mader SA, Hong CS, Perez RG.

Neurosci Lett. 2008 Apr 11;435(1):24-9. doi: 10.1016/j.neulet.2008.02.014. Epub 2008 Feb 12.

20.

Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons.

Goldberg MS, Fleming SM, Palacino JJ, Cepeda C, Lam HA, Bhatnagar A, Meloni EG, Wu N, Ackerson LC, Klapstein GJ, Gajendiran M, Roth BL, Chesselet MF, Maidment NT, Levine MS, Shen J.

J Biol Chem. 2003 Oct 31;278(44):43628-35. Epub 2003 Aug 20.

Supplemental Content

Support Center